CureVac is a clinical-stage biopharmaceutical company building a pipeline of mRNA-based medicines. The core premise is that mRNA can instruct human cells to produce specific proteins — either to trigger an immune response (vaccines and cancer immunotherapies) or to replace defective proteins (molecular therapy). CureVac has no approved products and generates no product revenue; all revenue comes from licensing and collaboration agreements. The primary partner is GSK, which controls CureVac's most advanced programs — influenza and COVID-19 vaccines — under a 2024 agreement that included a €400M upfront payment and up to €1.05B in future milestones, plus royalties on net sales. CureVac's current strategic priority is oncology, with programs targeting glioblastoma and squamous non-small cell lung cancer using off-the-shelf cancer immunotherapy candidates, alongside early-stage personalized cancer vaccine work using its RNA Printer manufacturing system. CureVac is also developing a proprietary mRNA vaccine for urinary tract infections. The company's technology platform centers on mRNA optimization, protein engineering, and LNP-based delivery systems. CureVac's strategy is to advance candidates through early clinical stages, then partner for late-stage development and commercialization. Additional upside could come from ongoing patent litigation against Pfizer and BioNTech over foundational mRNA technology. Following a 2024 restructuring that cut headcount roughly 30%, CureVac guides for a cash runway into 2028.